Dear colleagues of Orient Gene,

Good afternoon, everyone!

There are only a few days to go before the coming of the Chinese New Year. In the Chinese culture, it is a time to ring out the Old Year and ring in the New Year and greet relatives and friends. Here, first of all, on behalf of the Board of Directors of Orient Gene, I would like to extend my sincere wishes to you and your family!

In 2021, COVID-19 still goes on, and the continuous mutation of the virus is changing our lives rapidly. We should firmly believe that only by working together to combat it, can we pull through the difficult times. Mankind is a community with a shared future. We must work together to win the global battle in the epidemic containment.

Orient Gene (Orient Biotech 688298) had made full use of its professional strength to combat COVID-19 last year, with the help and support from the governments of China and other countries, enabling high-quality diagnostic reagents to reach the frontline of epidemic containment in all parts of the world in a timely and rapid manner and play a role in fighting against COVID-19.

Over the past year, we have completed a great number of orders. With limited time, heavy tasks, and strict requirements of customers for high quality, the whole company united as one, worked together day and night, and devoted ourselves to overcoming difficulties. Regardless of personal gains and losses, we fulfilled our duties with diligence and wisdom, and successfully completed various work, in which countless heroes and models have emerged and made extraordinary achievements in ordinary jobs.

Over the past year, we have made breakthroughs in scientific and technological innovation under the “five-in-one” strategic deployment, adhering to the principle of taking orders as the leading role, taking R&D as the guide, putting registration in the first place, taking production as the basis and quality as the soul. In addition, phased achievements have also been made in terms of the industrialization of biochips, liquid chips, 2019-NCoV-PCR detection / gene sequencing and other platforms.

Over the past year, according to the needs of industrial development, we set up new subsidiaries in Shanghai, Hangzhou, Beijing, Shenzhen and Hainan, especially Hainan Qikang Capital, made a preliminary attempt on mergers and acquisitions, creating conditions for the benign and rapid development of Orient Gene.

Over the past year, the company’s global strategic layout has taken a solid step. With continuously expanding scale, Healgen has begun to implement the layout of industrial base in Houston. It has begun to layout its industrial base in Houston. In 2022, the intensive development of production, R&D, sales and laboratory will be realized. Healton in Canada has enjoyed steady development. We have also set up a subsidiary in Scotland, which has laid a foundation for being integrated into the UK and European markets and providing technologies, products and services.

The year 2022 has arrived. For Orient Gene, it is an extremely important year, as well as a year full of challenges. Achievements only represent what we have done in the past, and the epidemic situation is still severe. We should carry forward the spirit of not being afraid of fatigue and continuously fighting, and continue to devote ourselves to combatting COVID-19. We should focus on our main business and strive to build three platforms including POCT, gene testing and liquid chip. We should adhere to scientific and technological innovation, constantly introduce high-end talents, strengthen the contact and cooperation with famous universities at home and abroad, and stick to high-quality development. We should strive to promote Orient Gene to a new level, strengthen internal governance and system construction under the guidance of the common program, so as to make Orient Gene become a great enterprise standing among the world’s high-end enterprises in the future.

Facing the future, we still need to confront many difficulties, and we still have many weak points. We will never bow to difficulties and challenges. We should have the fighting spirit of finding ways to solve any problem, so as to make Orient Gene have a more brilliant future!

General Manager Fang Xiaoliang

(Speech delivered by Fang Xiaoliang, General Manager of Orient Gene at the annual commendation conference of the company for the year 2021 on the afternoon of January 12)